IMIC(SZ:000516)2019-10-29 16:00Financial Performance - Operating revenue for the reporting period was ¥229,218,890.84, representing an increase of 11.67% year-on-year[2]. - Net profit attributable to shareholders was -¥25,305,833.53, a decrease of 209.22% compared to the same period last year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥52,589,879.08, a decrease of 291.82% year-on-year[2]. - Basic earnings per share for the reporting period was -¥0.013, a decrease of 208.33% year-on-year[2]. - Diluted earnings per share for the reporting period was also -¥0.013, reflecting a decrease of 208.33% compared to the previous year[2]. - The net profit for Q3 2019 was a loss of CNY 24,243,745.09, compared to a profit of CNY 30,922,284.37 in the same quarter of the previous year[28]. - The company's net profit for Q3 2019 was -25,288,245.88 CNY, compared to a net profit of 2,289,898,443.44 CNY in the same period last year, indicating a significant decline[35]. - The total comprehensive income for the period was CNY -27,422,178.03, compared to CNY 22,904,374.19 in the previous year[30]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥9,320,295,977.05, an increase of 27.56% compared to the previous year[2]. - The company's total assets amounted to approximately CNY 9.32 billion, an increase from CNY 7.31 billion at the end of 2018, representing a growth of about 27.5%[20]. - The company's current assets decreased to approximately CNY 1.83 billion from CNY 2.36 billion, reflecting a decline of about 22.5% year-over-year[20]. - The total liabilities of the company increased significantly to approximately CNY 3.94 billion from CNY 1.53 billion, marking an increase of about 157.5%[22]. - The company's long-term borrowings rose sharply to approximately CNY 2.97 billion from CNY 570.9 million, representing an increase of about 420.5%[22]. - The total liabilities as of September 30, 2019, were CNY 659,036,981.64, significantly higher than CNY 118,263,270.43 from the previous year, indicating a substantial increase[26]. - The company's equity attributable to shareholders was CNY 5,727,029,015.59, with retained earnings of CNY 3,146,937,939.36[47]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥77,316,381.17, an increase of 109.40% compared to the same period last year[2]. - Cash flow from operating activities for Q3 2019 was 669,166,590.84 CNY, a decrease from 1,971,514,269.94 CNY in the same period last year[40]. - The cash flow from operating activities showed a net outflow of 111,602,004.99 CNY, improving from a net outflow of 875,450,732.42 CNY in the previous period[43]. - The company received 2,623,047,117.64 CNY from financing activities, with a net cash flow from financing activities of 2,061,673,005.55 CNY, compared to a net outflow of 39,288,680.87 CNY in the previous period[42]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 90,863[5]. - The largest shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., held 18.88% of the shares, with a total of 372,093,150 shares[5]. Investment and Development - The newly opened Xi'an International Medical Center is expected to significantly expand the company's operational scale and enhance its market competitiveness, contributing to future performance growth[10]. - The company has invested a total of 80 million yuan in entrusted financial management products, with no overdue amounts[14]. - The company has established a regional medical cooperation network by signing agreements with over 50 grassroots hospitals in Shaanxi Province[9]. - Research and development expenses for Q3 2019 were CNY 1,760,287.96, indicating ongoing investment in innovation[28]. - The research and development expenses for the period were CNY 4,085,278.59, reflecting ongoing investment in innovation[34].